Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyntra Bio Inc (KYNB : NSDQ)

• Company Description    Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO. Number of Employees: 225

• Price / Volume Information    Yesterday's Closing Price: $7.79 Daily Weekly Monthly 20 Day Moving Average: 30,131 shares Shares Outstanding: 4.05 (millions) Market Capitalization: $31.51 (millions) Beta: 0.83 52 Week High: $21.94 52 Week Low: $4.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.87% -10.94% 12 Week -11.93% -12.81% Year To Date -11.28% -11.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 Bay Street Suite 100 #6009 - SAN FRANCISCO,CA 94158 USA ph: 415-978-1200 fax: 415-978-1902 ir@fibrogen.com http://www.fibrogen.com

• General Corporate Information    Officers Thane Wettig - Chief Executive Officer James A. Schoeneck - Chairman of the Board and Director David DeLucia - Senior Vice President and Chief Financial Officer Aoife Brennan - Director Jeffrey L. Edwards - Director Peer Information Kyntra Bio Inc (CORR.) Kyntra Bio Inc (RSPI) Kyntra Bio Inc (CGXP) Kyntra Bio Inc (BGEN) Kyntra Bio Inc (GTBP) Kyntra Bio Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31572Q881 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 4.05 Most Recent Split Date: 6.00 (0.04:1) Beta: 0.83 Market Capitalization: $31.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-17.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.80 EPS Growth vs. Year Ago Period: 62.12% vs. Previous Quarter: 52.37% Sales Growth vs. Year Ago Period: -97.68% vs. Previous Quarter: -20.18% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -26.27 06/30/25 - -27.34 Current Ratio 12/31/25 - - 09/30/25 - 3.71 06/30/25 - 1.04 Quick Ratio 12/31/25 - - 09/30/25 - 3.60 06/30/25 - 1.02 Operating Margin 12/31/25 - - 09/30/25 - -549.90 06/30/25 - -104.93 Net Margin 12/31/25 - - 09/30/25 - 2,598.55 06/30/25 - -3.86 Pre-Tax Margin 12/31/25 - - 09/30/25 - -630.78 06/30/25 - -163.36 Book Value 12/31/25 - - 09/30/25 - -0.99 06/30/25 - -50.10 Inventory Turnover 12/31/25 - - 09/30/25 - -1.59 06/30/25 - -0.65 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©